⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Baloxavir marboxil

بالوکساویر

⚠ Unverified

🦠 Antiinfectives For Systemic UseAnti-influenza (endonuclease inhibitor)

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications ⚠️ 1 interactions 🇺🇸 FDA approved (NDA) NDA210854 ATC J05AX25

Market / country: 🇺🇸 USA

Xofluza (US)

🧮 Dose calculator

Disease / regimen

Influenza (flu) · Regimen source: FDA Xofluza · 2.2, Tables 1–3

• Single dose, as soon as possible and within 48 h of symptom onset or contact. Not with dairy, calcium-fortified drinks, antacids, laxatives or calcium, iron, magnesium, selenium or zinc supplements. FDA Xofluza · 2.2 FDA Xofluza · 2.1

Formulation

Age *

Weight (kg) *

Enter age and weight.

🛡️ Safety & information

Contraindications

⛔ History of hypersensitivity to baloxavir (anaphylaxis, angioedema, urticaria, erythema multiforme). FDA Xofluza · 4

Important interactions

• Dairy, antacids and calcium, iron, magnesium, selenium and zinc supplements reduce absorption. FDA Xofluza · 2.1

Formulations

40 mg tablet — tablet 🇺🇸 USA FDA Xofluza · 3
80 mg tablet — tablet 🇺🇸 USA FDA Xofluza · 3
2 mg/mL suspension (40 mg/20 mL bottle after reconstitution) — suspension 🇺🇸 USA FDA Xofluza · 3 FDA Xofluza · 2.4

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Xofluza · 8.1
“Risk Summary There are no adequate and well-controlled studies with XOFLUZA in pregnant women to inform a drug-associated risk of adverse developmental outcomes.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Xofluza · 8.2
“Risk Summary There are no data on the presence of baloxavir marboxil in human milk, the effects on the breastfed infant, or the effects on milk production.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Xofluza · 8.4
“Pediatric Subjects (< 5 Years of Age) The safety and effectiveness of XOFLUZA for treatment and post-exposure prophylaxis of influenza in pediatric subjects less than 5 years of age, including neonates, have not been established [see Warnings and Precautions (5.2) and Microbiology (12.4) ].”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Xofluza · 8.5
“The safety and effectiveness of XOFLUZA in subjects 65 years of age and older has been established and is supported by one randomized, double-blind, controlled trial [see Clinical Studies (14.2) ] .”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA210854
DailyMed (FDA label)FDA Xofluza
MedlinePlus (NIH)Baloxavir Marboxil
WHO ATC/DDDJ05AX25
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Xofluza · 3 FDA Xofluza · 2.4 FDA Xofluza · 2.2, Tables 1–3 FDA Xofluza · 2.2 FDA Xofluza · 2.1 FDA Xofluza · 4 FDA Xofluza · 8.1 FDA Xofluza · 8.2 FDA Xofluza · 8.4 FDA Xofluza · 8.5 FDA Xofluza · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified

🔗 Similar drugs

For the same diseases

Oseltamivir